| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -42.3 | -25.6 |
| EPS (diluted, $ a share) | $-0.99 | $-1.32 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: IMUX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Immunic, Inc.: key numbers
- Share price
- $7.23Close, Nov 16
- Market cap
- $115M
- Shares outstanding
- 15.88MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Immunic, Inc.
All →Immunic Financial Results
Immunic, Inc. reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate, vidofludimus calcium. The company remains on track to report top-line data from its pivotal Phase 3 ENSURE trials in relapsing multiple sclerosis in December 2026, which could support a potential NDA submission.
- Term
- Q3 2026
“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history. We are evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding and addressing the needs of people living with MS.”
Erik Lundgren, Chief Executive Officer of Immunic
“Further, our Phase 3 ENSURE trials in relapsing MS continue to be on track to report top-line data in December 2026. Our teams remain focused on this readout and readiness for a potential NDA submission should the results be positive.”
Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic
Immunic Investor Presentation
Immunic, Inc. is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar on November 5, 2026. The company filed a formal investor presentation deck (Exhibit 99.1) to be used during the event, covering its development programs and clinical data for vidofludimus calcium.
Immunic Leadership Change
Dr. Duane Nash resigned from the Board of Directors of Immunic, Inc. on September 10, 2026. Following the resignation, the company reduced the size of its Board from ten to nine members.